Clinical and angiographic outcome after coronary arterial stenting with the carbostent

David Antoniucci, Antonio Bartorelli, Renato Valenti, Piero Montorsi, Giovanni M. Santoro, Franco Fabbiocchi, Leonardo Bolognese, Alessandro Loaldi, Maurizio Trapani, Daniela Trabattoni, Guia Moschi, Stefano Galli

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

The Carbostent is a new balloon-expandable, stainless steel, tubular stent with innovative multicellular design and unique turbostratic carbon coating (Carbofilm). This open nonrandomized 2-center study assesses the immediate and long-term clinical and angiographic outcomes after Carbostent implantation in patients with native coronary artery disease. The Carbostent was implanted in 112 patients with 132 de novo lesions. Most patients (55%) had unstable angina, and 38% of lesions were type B2-C. The mean lesion length was 12.5 ± 7.0 mm, and 29% of lesions were >15 mm in length. No stent deployment failure occurred, as well as acute or subacute stent thrombosis. The 6-month event-free survival was 84 ± 4%. One patient with a stented right coronary artery and no restenosis at the angiographic follow-up died after 6 months of fatal infarction due to abrupt closure of a nontarget vessel. In-hospital non-Q-wave myocardial infarction occurred in 1 patient, and 11 patients had repeat target lesion revascularization (target lesion revascularization rate 10%). The 6-month angiographic follow-up was obtained in 108 patients (96%) (127 lesions). Angiographic restenosis rate was 11%. The loss index was 0.29 ± 0.28. The results of this study indicate a potential benefit of Carbostent for the prevention of stent thrombosis and restenosis in these relatively high-risk patients. A larger trial is being planned to confirm these promising results. Copyright (C) 2000 Excerpta Medica Inc.

Original languageEnglish
Pages (from-to)821-825
Number of pages5
JournalThe American Journal of Cardiology
Volume85
Issue number7
DOIs
Publication statusPublished - Apr 1 2000

Fingerprint

Stents
Thrombosis
Stainless Steel
Unstable Angina
Infarction
Disease-Free Survival
Coronary Artery Disease
Coronary Vessels
Carbon
Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical and angiographic outcome after coronary arterial stenting with the carbostent. / Antoniucci, David; Bartorelli, Antonio; Valenti, Renato; Montorsi, Piero; Santoro, Giovanni M.; Fabbiocchi, Franco; Bolognese, Leonardo; Loaldi, Alessandro; Trapani, Maurizio; Trabattoni, Daniela; Moschi, Guia; Galli, Stefano.

In: The American Journal of Cardiology, Vol. 85, No. 7, 01.04.2000, p. 821-825.

Research output: Contribution to journalArticle

Antoniucci, David ; Bartorelli, Antonio ; Valenti, Renato ; Montorsi, Piero ; Santoro, Giovanni M. ; Fabbiocchi, Franco ; Bolognese, Leonardo ; Loaldi, Alessandro ; Trapani, Maurizio ; Trabattoni, Daniela ; Moschi, Guia ; Galli, Stefano. / Clinical and angiographic outcome after coronary arterial stenting with the carbostent. In: The American Journal of Cardiology. 2000 ; Vol. 85, No. 7. pp. 821-825.
@article{c68a63e07e014e7090c06c5160143ae8,
title = "Clinical and angiographic outcome after coronary arterial stenting with the carbostent",
abstract = "The Carbostent is a new balloon-expandable, stainless steel, tubular stent with innovative multicellular design and unique turbostratic carbon coating (Carbofilm). This open nonrandomized 2-center study assesses the immediate and long-term clinical and angiographic outcomes after Carbostent implantation in patients with native coronary artery disease. The Carbostent was implanted in 112 patients with 132 de novo lesions. Most patients (55{\%}) had unstable angina, and 38{\%} of lesions were type B2-C. The mean lesion length was 12.5 ± 7.0 mm, and 29{\%} of lesions were >15 mm in length. No stent deployment failure occurred, as well as acute or subacute stent thrombosis. The 6-month event-free survival was 84 ± 4{\%}. One patient with a stented right coronary artery and no restenosis at the angiographic follow-up died after 6 months of fatal infarction due to abrupt closure of a nontarget vessel. In-hospital non-Q-wave myocardial infarction occurred in 1 patient, and 11 patients had repeat target lesion revascularization (target lesion revascularization rate 10{\%}). The 6-month angiographic follow-up was obtained in 108 patients (96{\%}) (127 lesions). Angiographic restenosis rate was 11{\%}. The loss index was 0.29 ± 0.28. The results of this study indicate a potential benefit of Carbostent for the prevention of stent thrombosis and restenosis in these relatively high-risk patients. A larger trial is being planned to confirm these promising results. Copyright (C) 2000 Excerpta Medica Inc.",
author = "David Antoniucci and Antonio Bartorelli and Renato Valenti and Piero Montorsi and Santoro, {Giovanni M.} and Franco Fabbiocchi and Leonardo Bolognese and Alessandro Loaldi and Maurizio Trapani and Daniela Trabattoni and Guia Moschi and Stefano Galli",
year = "2000",
month = "4",
day = "1",
doi = "10.1016/S0002-9149(99)00874-7",
language = "English",
volume = "85",
pages = "821--825",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Clinical and angiographic outcome after coronary arterial stenting with the carbostent

AU - Antoniucci, David

AU - Bartorelli, Antonio

AU - Valenti, Renato

AU - Montorsi, Piero

AU - Santoro, Giovanni M.

AU - Fabbiocchi, Franco

AU - Bolognese, Leonardo

AU - Loaldi, Alessandro

AU - Trapani, Maurizio

AU - Trabattoni, Daniela

AU - Moschi, Guia

AU - Galli, Stefano

PY - 2000/4/1

Y1 - 2000/4/1

N2 - The Carbostent is a new balloon-expandable, stainless steel, tubular stent with innovative multicellular design and unique turbostratic carbon coating (Carbofilm). This open nonrandomized 2-center study assesses the immediate and long-term clinical and angiographic outcomes after Carbostent implantation in patients with native coronary artery disease. The Carbostent was implanted in 112 patients with 132 de novo lesions. Most patients (55%) had unstable angina, and 38% of lesions were type B2-C. The mean lesion length was 12.5 ± 7.0 mm, and 29% of lesions were >15 mm in length. No stent deployment failure occurred, as well as acute or subacute stent thrombosis. The 6-month event-free survival was 84 ± 4%. One patient with a stented right coronary artery and no restenosis at the angiographic follow-up died after 6 months of fatal infarction due to abrupt closure of a nontarget vessel. In-hospital non-Q-wave myocardial infarction occurred in 1 patient, and 11 patients had repeat target lesion revascularization (target lesion revascularization rate 10%). The 6-month angiographic follow-up was obtained in 108 patients (96%) (127 lesions). Angiographic restenosis rate was 11%. The loss index was 0.29 ± 0.28. The results of this study indicate a potential benefit of Carbostent for the prevention of stent thrombosis and restenosis in these relatively high-risk patients. A larger trial is being planned to confirm these promising results. Copyright (C) 2000 Excerpta Medica Inc.

AB - The Carbostent is a new balloon-expandable, stainless steel, tubular stent with innovative multicellular design and unique turbostratic carbon coating (Carbofilm). This open nonrandomized 2-center study assesses the immediate and long-term clinical and angiographic outcomes after Carbostent implantation in patients with native coronary artery disease. The Carbostent was implanted in 112 patients with 132 de novo lesions. Most patients (55%) had unstable angina, and 38% of lesions were type B2-C. The mean lesion length was 12.5 ± 7.0 mm, and 29% of lesions were >15 mm in length. No stent deployment failure occurred, as well as acute or subacute stent thrombosis. The 6-month event-free survival was 84 ± 4%. One patient with a stented right coronary artery and no restenosis at the angiographic follow-up died after 6 months of fatal infarction due to abrupt closure of a nontarget vessel. In-hospital non-Q-wave myocardial infarction occurred in 1 patient, and 11 patients had repeat target lesion revascularization (target lesion revascularization rate 10%). The 6-month angiographic follow-up was obtained in 108 patients (96%) (127 lesions). Angiographic restenosis rate was 11%. The loss index was 0.29 ± 0.28. The results of this study indicate a potential benefit of Carbostent for the prevention of stent thrombosis and restenosis in these relatively high-risk patients. A larger trial is being planned to confirm these promising results. Copyright (C) 2000 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034175826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034175826&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)00874-7

DO - 10.1016/S0002-9149(99)00874-7

M3 - Article

VL - 85

SP - 821

EP - 825

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -